Progress of treatment with Fms-like receptor tyrosine kinase-3 inhibitors for acute myelogenous leukemia

Fms-like receptor tyrosine kinase-3 (FLT3) is a member of the class Ⅲ receptor tyrosine kinase family. Coexpression of wild-type receptor with its ligand,internal tandem duplications (ITD) and activation loop mutations lead to the consistent expression of phosphorylation-activited FLT3. These aberrant expressions of FLT3 have been detected in most acute myelogenous leukemia (AML) providing a prognostic significance. FLT3 inhibitors mainly include 5 varieties and heat shock protein 90(HSP90)inhibitor as well. These agents have shown promising effect on the therapy of AML in experiments and early clinical trials.